Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

81.30GBp
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
81.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,060,193
52-wk High
90.15
52-wk Low
65.85

Select another date:

Mon, Jun 10 2019

Photo

Drugmaker Vectura parts ways with CEO Ward-Lilley

British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

UPDATE 1-Drugmaker Vectura parts ways with CEO Ward-Lilley

June 10 British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

Drugmaker Vectura CEO James Ward-Lilley to step down

June 10 British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.

BRIEF-Vectura Group To Receive $2.5 Mln Milestone Payment For QVM149 Submission

* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

Select another date: